News Archive

• 07.10.2026  |  CARB-X aims to accelerate neonatal sepsis diagnostic development via innovative funding mechanism

  GENOMEWEB | Infant bloodstream infections are a vexing global health challenge in need of new diagnostic solutions. A Center for Global Development program called NeoTest is now aiming to help test makers bridge the gap to market.

  Full Story

• 07.08.2026  |  Boston University-led biopharmaceutical accelerator boosts new drugs’ chances of success, study finds

  THE BRINK | CARB-X-backed novel therapeutics to combat antimicrobial resistance are nearly five times more likely to reach clinical development.

  Full Story

• 06.25.2026  |  A ‘nightmare bacteria’ is surging while investment in antibiotics lags

  PHARMAVOICE | Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.

  Full Story

• 04.08.2026  |  One Health : des « Engagements de Lyon » à une approche mondiale

  PHARMACEUTIQUES | Organisé à Lyon, le One Health Summit veut marquer un tournant stratégique, de la prévention des pandémies à la lutte contre la résistance aux antimicrobiens.

  Full Story

• 04.08.2026  |  EU pledges €700m to Global Fund to tackle worldwide health challenges

  INNOVATION NEWS NETWORK | The European Commission has announced plans to commit €700m to the Global Fund, reinforcing its position as a central player in global health financing.

  Full Story

• 04.08.2026  |  EU invests €30m to fight antimicrobial resistance

  PHARMAPHORUM | The EU has pledged €30 million ($35 million) in funding for medical countermeasures to antimicrobial resistance (AMR), earmarked for the discovery and development of new antibacterial medicines.

  Full Story

• 04.07.2026  |  Global agreement announced at G7 One Health Summit to accelerate access to diagnostics and responses to rising health threats

  BIOMERIEUX | A coalition of more than 20 international partners announced the Global One Health Diagnostics Access Compact (GO-Dx) during the G7 One Health Summit in Lyon, France.

  Full Story

• 03.30.2026  |  Lægemiddelresistens – en global sundhedskrise

  NOVO NORDISK FOUNDATION | Dette er den fjerde del i en serie af vores administrerende direktør, Mads Krogsgaard Thomsen, om, hvordan Novo Nordisk Fonden er i forandring.

  Full Story

• 01.30.2026  |  In brief this week: Natera, Revvity, Becton Dickinson, Wellcome, CARB-X

  360DX | Global charitable organization Wellcome and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced this week that they haverenewed their partnership.

  Full Story

• 01.29.2026  |  CARB-X receives $60 million from Wellcome to support early-stage antibiotic R&D

  CIDRAP | CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) said yesterday that it will receive $60 million in funding over the next two years from global charitable foundation Wellcome.

  Full Story